Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Express Scripts
Baxter
AstraZeneca
Dow

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR ORAPRED ODT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Orapred Odt

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00079105 ↗ A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years Completed Newcastle-upon-Tyne Hospitals NHS Trust Phase 2 2004-01-01 RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating older patients with previously untreated Hodgkin's lymphoma.
NCT00798616 ↗ Steroids Helping Albuterol Responders Exclusively Withdrawn University Hospitals Cleveland Medical Center N/A 1969-12-31 The purpose of the study is to determine whether corticosteroids are beneficial to children with bronchiolitis whose breathing gets better after being given a breathing treatment with albuterol.
NCT01211665 ↗ Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Terminated Elan Pharmaceuticals Phase 4 2010-09-01 The objectives of this study are to explore the effects of administering high-dose corticosteroids to participants who developed progressive multifocal leukoencephalopathy (PML) while on natalizumab as measured by time-course change in functional status based on Karnofsky Performance Status Index through 6 months following the completion of plasma exchange (PLEX; or equivalent), survival at 6 months following the completion of PLEX (or equivalent), and incidence and severity of adverse events (AEs) and serious adverse events (SAEs); to characterize the evolution of immune reconstitution inflammatory syndrome (IRIS) as measured by time course changes in Global Clinical Impression of Improvement (GCI-I), Symbol Digit Modalities Test (SDMT), brain magnetic resonance imaging (MRI), magnetoencephalography (MEG), chemokines, cytokines, C-reactive protein (CRP), John Cunningham virus (JCV) load and cell count in cerebrospinal fluid (CSF); and to characterize the time course elimination of serum natalizumab concentrations in the study population following the last PLEX (or equivalent) procedure.
NCT01211665 ↗ Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Terminated Biogen Phase 4 2010-09-01 The objectives of this study are to explore the effects of administering high-dose corticosteroids to participants who developed progressive multifocal leukoencephalopathy (PML) while on natalizumab as measured by time-course change in functional status based on Karnofsky Performance Status Index through 6 months following the completion of plasma exchange (PLEX; or equivalent), survival at 6 months following the completion of PLEX (or equivalent), and incidence and severity of adverse events (AEs) and serious adverse events (SAEs); to characterize the evolution of immune reconstitution inflammatory syndrome (IRIS) as measured by time course changes in Global Clinical Impression of Improvement (GCI-I), Symbol Digit Modalities Test (SDMT), brain magnetic resonance imaging (MRI), magnetoencephalography (MEG), chemokines, cytokines, C-reactive protein (CRP), John Cunningham virus (JCV) load and cell count in cerebrospinal fluid (CSF); and to characterize the time course elimination of serum natalizumab concentrations in the study population following the last PLEX (or equivalent) procedure.
NCT01391793 ↗ Corticosteroids for Children With Febrile Urinary Tract Infections Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 2011-09-01 In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Orapred Odt

Condition Name

Condition Name for Orapred Odt
Intervention Trials
Status Asthmaticus 1
Bronchiolitis 1
Stomatitis 1
Grafting, Corneal 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Orapred Odt
Intervention Trials
Syndrome 1
Mucositis 1
Leukoencephalopathy, Progressive Multifocal 1
Breast Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Orapred Odt

Trials by Country

Trials by Country for Orapred Odt
Location Trials
United States 12
United Kingdom 3
Germany 2
Thailand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Orapred Odt
Location Trials
Ohio 2
Florida 1
Oregon 1
California 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Orapred Odt

Clinical Trial Phase

Clinical Trial Phase for Orapred Odt
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Orapred Odt
Clinical Trial Phase Trials
Completed 3
Active, not recruiting 2
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Orapred Odt

Sponsor Name

Sponsor Name for Orapred Odt
Sponsor Trials
Oregon Health and Science University 1
University Hospitals Cleveland Medical Center 1
Winston Chamberlain, MD, PhD 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Orapred Odt
Sponsor Trials
Other 10
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Merck
Moodys
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.